SiBone (SIBN) & The Competition Head-To-Head Review

SiBone (NASDAQ:SIBN) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare SiBone to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for SiBone and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	7	0	2.75
SiBone Competitors	4295	10586	18372	832	2.46

SiBone presently has a consensus target price of $25.00, indicating a potential upside of 4.48%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.36%. Given SiBone’s competitors higher possible upside, analysts plainly believe SiBone has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares SiBone and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SiBone	$200.93 million	-$18.90 million	-77.19
SiBone Competitors	$1.87 billion	$137.20 million	5.94

SiBone’s competitors have higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares SiBone and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-6.20%	-7.57%	-5.55%
SiBone Competitors	-303.57%	-175.14%	-22.20%

Volatility & Risk

SiBone has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, SiBone’s competitors have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Insider and Institutional Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SiBone competitors beat SiBone on 7 of the 13 factors compared.

SiBone Company Profile

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.